Immune cell infusion plus transplant for tough leukemia
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new two-step approach for people with hard-to-treat leukemia. First, you get chemotherapy plus an infusion of special immune cells from a partially matched donor, then a stem cell transplant. The goal is to see if this is safe and helps the leukemia go away.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 15 years old or older.
- Your leukemia has come back or not gotten better with standard treatment.
- You have a donor (at least 18 years old) who is a partial blood type match and willing to donate stem cells (and possibly a second donor for a later transplant).
- Your liver and kidney function tests are within safe limits, and your heart pumps well (LVEF above 50%).
- You are not pregnant, nursing, or unwilling to use birth control, and you don't have serious infections, heart disease, or other life-threatening conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a stem cell transplant from a matched sibling donor, followed by extra immune cells to help prevent relapse in people with high-risk acute myeloid leukemia (AML) who are in remission. It aims to improve outcomes by boosting the immune system's ability to fight any remaining leukemia cells.
This Phase 2 trial tests whether a specific stem cell transplant method (from a related “half-matched” donor) plus conditioning chemo and radiation can improve outcomes for several blood cancers. It may help people whose cancer is in remission but still considered high risk, or those who have had limited response after prior treatment.
This Phase 1 trial tests a special bone marrow transplant using a related “half-matched” donor (haploidentical), without a specific immune-suppressing medicine (“IS-free”). It’s for adults with certain high-risk AML or MDS to see if this approach can improve control of the disease while tracking safety.
This trial tests a special transplant approach for people with high-risk acute leukemia. It uses a stronger dose of radiation before transplant, followed by an infusion of immune cells (regulatory and conventional T cells) to help the transplant work better and fight the leukemia.
This trial tests a specific transplant method using a half-matched donor to treat high-risk acute myeloid leukemia (AML), a type of blood cancer. It aims to reduce complications and improve outcomes for patients who have not responded to other treatments.
This Phase 2 study tests ways to lower the risk of graft-versus-host disease (GVHD), a serious complication after an allogeneic stem cell transplant from a matched donor. It is for people with acute leukemia or MDS who are going to receive intensive conditioning therapy, aiming to improve safety while keeping the transplant effective.
Hear when a new Refractory Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.